Phase II pilot study of intravenous high-dose Interferon with or without maintenance treatment in melanoma at high risk of recurrence.
Payne, M Argyropoulou, K McAleer, J Farrugia, D Davidson, N Kelly, C Chao, D Marshall, E Han, C
Payne, M
Argyropoulou, K
McAleer, J
Farrugia, D
Davidson, N
Kelly, C
Chao, D
Marshall, E
Han, C
Citations
Altmetric:
Abstract
High-dose interferon alfa-2b (HDI) has emerged as a potentially effective adjuvant therapy in patients with resected melanoma at high risk of recurrence. Evidence suggests it may be the early, very-high-dose part of the regimen that is critical. This pilot study sought to provide an early indication of whether the same effects can be achieved with the intravenous component of HDI alone and inform the feasibility and design of a phase III trial.
Description
Date
2014-01-20
Publisher
Collections
Keywords
Type
Article
Citation
Phase II pilot study of intravenous high-dose Interferon with or without maintenance treatment in melanoma at high risk of recurrence. 2014, 32 (3):185-90 J Clin Oncol